T22

2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile

Find entries where: T22

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile
Synonyms	Alogliptin
Identifiers	2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-pyrimidin-1-yl]methyl]benzonitrile
Formula	C₁₈ H₂₁ N₅ O₂
Molecular Weight	339.392
Type	NON-POLYMER
Isomeric SMILES	CN1C(=O)C=C(N(C1=O)Cc2ccccc2C#N)N3CCC[C@H](C3)N
InChI	InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
InChIKey	ZSBOMTDTBDDKMP-OAHLLOKOSA-N

Chemical Details
Formal Charge	0
Atom Count	46
Chiral Atom Count	1
Bond Count	48
Aromatic Bond Count	6

Drug Info: DrugBank

DrugBank ID	DB06203
Name	Alogliptin
Groups	approved
Description	Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Synonyms	Alogliptin Alogliptina Alogliptine Alogliptinum Alogliptin benzoate
Brand Names	Oseni Vipdomet Alogliptin Vipidia Kazano Incresync Alogliptin and Pioglitazone Alogliptin and Metformin Hydrochloride Nesina
Indication	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Categories	Agents causing angioedema Alimentary Tract and Metabolism Blood Glucose Lowering Agents Cytochrome P-450 CYP2D6 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates DPP-IV Inhibitors Drugs that are Mainly Renally Excreted Drugs Used in Diabetes Enzyme Inhibitors Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Incretins Oral Hypoglycemics Protease Inhibitors Pyrimidines Pyrimidinones
ATC-Code	A10BD13 A10BD09 A10BH04
CAS number	850649-61-5

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Dipeptidyl peptidase 4	MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLK...	unknown	inhibitor
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Cytochrome P450 2D6	MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682